bluebird bio, Inc. (BLUE)
| Market Cap | 325.14M |
| Revenue (ttm) | 9.41M |
| Net Income (ttm) | -95.96M |
| Shares Out | 106.95M |
| EPS (ttm) | -0.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,598,705 |
| Open | 3.07 |
| Previous Close | 3.02 |
| Day's Range | 2.97 - 3.16 |
| 52-Week Range | 2.78 - 8.58 |
| Beta | 0.93 |
| Analysts | Buy |
| Price Target | 7.28 (+139.47%) |
| Earnings Date | Nov 6, 2023 |
About BLUE
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and effic... [Read more]
Financial Performance
In 2022, Bluebird Bio's revenue was $3.60 million, a decrease of -1.77% compared to the previous year's $3.66 million. Losses were -$266.58 million, -67.47% less than in 2021.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for BLUE stock is "Buy." The 12-month stock price forecast is $7.28, which is an increase of 139.47% from the latest price.
News
Are Gene Therapy Stocks The Market's Next Big Winners?
It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD...
bluebird bio Announces September Investor Events
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that members of the management team will participate in fireside chats at the following upcoming investor conferen...
bluebird bio Confirms That FDA Has Communicated That Advisory Committee Meeting Will Not Be Scheduled for lovo-cel Gene Therapy for Sickle Cell Disease
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has communicated that an advisory committee meeting will not be s...
bluebird bio Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the second quarter ended June 30, 2...
bluebird bio to Host Second Quarter 2023 Financial Results Conference Call and Provide Commercial Update
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced it will hold a conference call to discuss second quarter 2023 financial results and provide a commercial update on...
U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 mln
An influential U.S. drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals /CRISPR Therapeutics and bluebird bio to as much as $2.05 mln, saying...
bluebird bio Announces FDA Priority Review of the Biologics License Application for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lovotibe...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE
NEW YORK , May 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Such investors are advised to ...
bluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the first quarter ended March 31, 2...
bluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company's first quarter financial results, including commercial, regulatory and operational updates, will...
bluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lovot...
bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlights for the fourth quarter and full year en...
bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a publi...
bluebird bio, Inc. Announces Proposed Public Offering of Common Stock
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced that it has commenced an underwritten public offering of 20,000,000 shares of its common stock. blu...
bluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) (the Company) today announced updates to be presented at the 41st Annual J.P. Morgan Healthcare conference including commercial...
bluebird bio Sells Second Priority Review Voucher for $95 Million
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a definitive agreement to sell its second Rare Pediat...
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the 41st Annua...
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that Joseph Vittiglio, JD, has been appointed Chief Business and Legal Officer. Vittiglio brings more than 20 y...
FDA Lifts Partial Clinical Hold for bluebird bio's Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) lifted its partial clinical hold for patients under the age of...
New Data from bluebird bio's Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual Meeting
SOMERVILLE, Mass.--(BUSINESS WIRE)--Today new and updated data from bluebird bio inc.'s (NASDAQ: BLUE) gene therapy programs in beta-thalassemia and sickle cell disease were presented at the 64th Am...
bluebird bio Sells Priority Review Voucher for $102 Million
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disea...
bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
SOMERVILLE, Mass.
bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference
SOMERVILLE, Mass.
World's Most Expensive Drugs Can't Cure What Ails This Biotech
Bluebird Bio has received a lot of attention for pricing two FDA-approved gene therapies at around $3 million annually, but its financial future remains uncertain.
2 Small Caps for Growth-Focused Investors
Investors seeking opportunities among growth stocks could be interested in the following small caps, as they represent companies whose trailing 12-month net income per share has improved significantly...